TA Announces Completion of Tender Offer for Nexus AG
TA Associates (“TA” or the “Firm”), a leading global private equity firm, announced today that its holding company, Project Neptune BidCo GmbH, successfully completed its tender offer (the “Offer”) to acquire all outstanding ordinary shares and stock acquisition rights of Nexus AG (“Nexus”), a leading European software company in the e-health sector. This transaction, undertaken in partnership with the Management Board of Nexus, marks a significant milestone in Nexus’s journey, positioning the Company for continued growth and innovation away from a stock market environment.
The Offer, which commenced on November 11, 2024, for 70.00 Euro in cash per share, was completed as scheduled on January 3, 2025, at the end of the additional acceptance period. At the time of completion, the Offer was accepted for 16,402,668 Nexus shares, representing approximately 94.95% of all Nexus shares, including 26.9% which TA secured through irrevocable undertakings with key Nexus shareholders. All of such shares have been accepted for payment in accordance with the terms of the Offer, and TA expects to promptly pay for such shares.
Settlement of the Offer remains subject to customary regulatory conditions, including antitrust and foreign investment control clearances. Subject to the fulfillment of these conditions, settlement of the Offer is expected in Q1 2025, at which point TA intends to delist Nexus from the Frankfurt Stock Exchange, increasing its operational flexibility to focus on long-term growth initiatives.
“TA has followed Nexus's growth trajectory for many years and admired its leadership in the European e-health market,” said Stefan Dandl, Director at TA. “With its modern technology platform, expansive product portfolio and unwavering focus on customer satisfaction, we believe Nexus is well positioned to capitalize on the growing demand for digital healthcare solutions.”
By taking Nexus private, TA aims to empower the Company to further strengthen its customer offerings, pursue strategic acquisitions and invest significantly in research and development, particularly in areas such as cloud computing and AI-driven solutions.
“We're excited to partner with Ingo and the exceptional Nexus team to further advance healthcare software solutions that empower healthcare providers and improve patient outcomes,” added Birker Bahnsen, Managing Director at TA.
“Nexus has consistently delivered double-digit growth and strong financial performance,” said Dr. Ingo Behrendt, CEO of Nexus AG. “We believe our strategic partnership with TA will accelerate our ability to develop cutting-edge solutions that enhance the efficiency and quality of care for our customers. With access to significant new resources and greater flexibility to leverage industry tailwinds, we will continue driving value for healthcare providers who trust our platforms to power their digital transformation.”
“After careful consideration, The Supervisory Board and Management Board of Nexus AG unanimously concluded that this strategic partnership represents the best path forward for Nexus, its shareholders and customers,” shared Dr. Hans-Joachim König, Chairman of the Supervisory Board of Nexus AG. “We believe it creates immediate value for Nexus and are excited by the opportunities ahead.”
About TA Associates
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. Further information on TA can be found at www.ta.com.
About Nexus AG
Nexus AG develops and distributes software solutions for the international healthcare market. With the clinical information system (Nexus / KIS) and the integrated diagnostic modules, we now have a uniquely broad and interoperable product range that can cover almost all functional requirements of hospitals, psychiatric clinics, rehabilitation and diagnostic centers within our own product families. Nexus AG employs around 2,030 people, owns sites in nine European countries and supports customers in further 71 countries, in some cases via certified dealers. Due to the continuously growing demand for Nexus products, we have been able to build up a large customer base in recent years and regularly achieve increasing sales and results. Further information on Nexus AG can be found at www.nexus-ehealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113838688/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip is One of the Top CPaaS Providers in Metrigy’s CPaaS MetriRank Report14.1.2025 10:43:00 CET | Press release
The reportshows Infobip's leadership in the CPaaS market for the second year running Global communications platformInfobiphas been ranked as the second-highest scoring Communications Platform as a Service (CPaaS) provider in analyst firm Metrigy’s latest CPaaS MetriRank Report. Infobip stands out for its stellar product mix and outstanding customer sentiment and customer business success scores, confirming its status as a CPaaS market leader. The 2024 MetriRank CPaaS report ranks the top players by market share in the global CPaaS market, comparing financials, market share momentum, product mix, customer sentiment, and customer business success. Infobip is recognized by Metrigy for its expanding go-to-market strategy, self-service capabilities and CPaaS ecosystem partnerships.Infobip scored maximum points for product mix, with a strong portfolio that includes not only a full range of communications APIs, but also CPaaS X, AI-powered omnichannel solutions, and other innovative offerings
Sodali & Co Appoints Andrew Benett as Chief Executive Officer14.1.2025 10:00:00 CET | Press release
Sodali & Co (the ‘firm’ or ‘Sodali’ and formerly Morrow Sodali), a leading global advisory firm, is pleased to announce the appointment of Andrew Benett as Chief Executive Officer, effective immediately. He will be based in New York. Andrew has a 30-year career across global advisory businesses including Global CEO and Chief Strategy Officer at Havas Creative Group, Chief Commercial Officer of Bloomberg Media and CEO and Executive Chair of Harte Hanks Inc., the NASDAQ-listed publishing company. Most recently, Andrew was a Partner at PwC working with clients to deliver organic and inorganic growth, as well as leading corporate strategy initiatives for the firm. He is an acknowledged strategist, author of three business books, and a fellow of the Aspen Institute. Andrew was appointed after a global search following Alvise Recchi stepping down as CEO last September. He joins the firm at an important moment in its development. In the last two years, Sodali has transformed at speed from a s
Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology14.1.2025 10:00:00 CET | Press release
Bioptimus announces a $76M funding milestone, with the latest injection of $41M led by Cathay Innovation less than 12 months from its initial seed roundSince the successful release of the largest AI foundation model for pathology in July, the company has been continuing its groundbreaking work and is now poised to release a breakthrough new multi-scale, multi-modal foundation model for biology in 2025The new model will allow the simulation of biology at unprecedented scale and dimension, creating biological innovation for medical, biotech, cosmetic industries, and beyond Bioptimus, the pioneering AI foundation model company, announced today that it has reached a significant funding milestone of $76 million. This total includes a $41 million cash injection, led by Cathay Innovation with participation from prominent investors, including Sofinnova Partners, Bpifrance through its Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and ang
Cirium Ascend Consultancy Lands ‘Appraiser of the Year’ Title for the 10th Time14.1.2025 09:00:00 CET | Press release
2025 marks the third year in a row Cirium has been awarded the prestigious accolade, recognising their unparalleled expertise in the field Cirium Ascend Consultancy, part of the world’s most trusted source of aviation analytics, Cirium, has once again landed Airline Economics’ prestigious title of ‘Appraiser of the Year’ at an award ceremony last night. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113971776/en/ Cirium awarded 'Appraiser of the Year' (Photo: Business Wire) This marks the tenth win for Cirium Ascend Consultancy, demonstrating its unparalleled expertise within aviation consultancy and underlining its unwavering commitment to excellence, transparency and accuracy. The annual award was presented to Rob Morris, Global Head of Cirium Ascend Consultancy, at the Airline Economics Aviation 100 Global Leaders Awards 2025 in Dublin, Ireland, which celebrates the best companies, individuals and transactions in the a
Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth14.1.2025 07:00:00 CET | Press release
Almirall's unique dedication to medical dermatology and innovation - combined with its commercial excellence - fuel an era of sustained double-digit growth (net sales CAGR 2023-2030) and profitability enabling the company to reach more patients with relevant and impactful productsGrowth of Almirall’s psoriasis and atopic dermatitis franchises is anticipated to lead to over 800 million in annual peak sales in biologics, driven by Ebglyss® and Ilumetri®Strategic investments in commercial excellence, R&D and science leadership provide the basis for realising Almirall’s market potential as European leader in medical dermatology Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 202
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom